Jordan Gauthier

4.8k total citations · 2 hit papers
112 papers, 2.0k citations indexed

About

Jordan Gauthier is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jordan Gauthier has authored 112 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 23 papers in Immunology and 22 papers in Molecular Biology. Recurrent topics in Jordan Gauthier's work include CAR-T cell therapy research (76 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Lymphoma Diagnosis and Treatment (15 papers). Jordan Gauthier is often cited by papers focused on CAR-T cell therapy research (76 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Lymphoma Diagnosis and Treatment (15 papers). Jordan Gauthier collaborates with scholars based in United States, France and South Africa. Jordan Gauthier's co-authors include Cameron J. Turtle, Vipul Sheth, Ibrahim Yakoub‐Agha, David G. Maloney, Alexandre V. Hirayama, Stanley R. Riddell, Kevin A. Hay, Mazyar Shadman, Rachel N. Steinmetz and Barbara S. Pender and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jordan Gauthier

100 papers receiving 2.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

2020 227 citations Jordan Gauthier, Alexandre V. Hirayama et al. Blood profile →
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

2021 202 citations Jordan Gauthier et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jordan Gauthier United States	20	1.4k	454	389	375	345	112	2.0k
Cecilia C.S. Yeung United States	18	1.3k 0.9×	365 0.8×	222 0.6×	392 1.0×	379 1.1×	81	2.0k
Sandra H. Thomas United States	25	978 0.7×	409 0.9×	471 1.2×	351 0.9×	386 1.1×	60	1.9k
Sairah Ahmed United States	23	1.4k 1.0×	517 1.1×	484 1.2×	277 0.7×	597 1.7×	219	2.1k
Alison Gulbis United States	15	1.9k 1.3×	826 1.8×	161 0.4×	439 1.2×	483 1.4×	72	2.6k
Rammurti T. Kamble United States	17	1.4k 1.0×	514 1.1×	116 0.3×	545 1.5×	632 1.8×	66	2.1k
Qian Wu United States	20	1.3k 0.9×	419 0.9×	238 0.6×	489 1.3×	422 1.2×	123	2.0k
Jenna Voutsinas United States	17	1.3k 0.9×	281 0.6×	276 0.7×	392 1.0×	270 0.8×	78	1.6k
Aleksandr Lazaryan United States	21	797 0.6×	443 1.0×	275 0.7×	186 0.5×	678 2.0×	103	1.7k
Heinz‐August Horst Germany	17	1.5k 1.0×	295 0.6×	696 1.8×	332 0.9×	1.2k 3.5×	28	2.8k
Christoph Faul Germany	22	1.3k 0.9×	608 1.3×	445 1.1×	278 0.7×	1.1k 3.2×	82	2.5k

Countries citing papers authored by Jordan Gauthier

Since Specialization

Citations

This map shows the geographic impact of Jordan Gauthier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordan Gauthier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordan Gauthier more than expected).

Fields of papers citing papers by Jordan Gauthier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordan Gauthier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordan Gauthier. The network helps show where Jordan Gauthier may publish in the future.

Co-authorship network of co-authors of Jordan Gauthier

This figure shows the co-authorship network connecting the top 25 collaborators of Jordan Gauthier. A scholar is included among the top collaborators of Jordan Gauthier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordan Gauthier. Jordan Gauthier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krantz, Elizabeth M., Julián B. Muñoz, Andrew J. Cowan, et al.. (2025). Distinct Patterns of Pathogen-Specific and Non-Specific Immune Reconstitution after CD19/20- Versus BCMA-Targeted CAR-T Cell Therapy. Transplantation and Cellular Therapy. 31(2). S71–S71.

Li, Yimei, Yang Qiao, Jordan Gauthier, et al.. (2025). A Novel R Shiny Tool TVCurveTM for Survival Analysis with Time-Varying Covariate in Oncology Clinical Studies: Overcoming Biases and Enhancing Collaboration. Transplantation and Cellular Therapy. 31(2). S23–S24.

Wu, Qian, et al.. (2025). A Practical Guide to Competing Risk Analysis for Transplant and Cell Therapy Research. Transplantation and Cellular Therapy.

Poh, Christina, Victor A. Chow, Ryan C. Lynch, et al.. (2024). Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis. Transplantation and Cellular Therapy. 30(2). S33–S33.

Huang, Jennifer J., Emily C. Liang, Andrew J. Portuguese, et al.. (2024). Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.. Journal of Clinical Oncology. 42(16_suppl). 7034–7034. 2 indexed citations

Huang, Jennifer J., Ryan Basom, Andrea Kalus, et al.. (2024). Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma. Blood. 144(Supplement 1). 7132–7132. 1 indexed citations

Hirayama, Alexandre V., Jocelyn H. Wright, Kimberly S. Smythe, et al.. (2024). PD‐L1⁺ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B‐cell lymphoma microenvironment impact CD19 CAR‐T cell immunotherapy efficacy. HemaSphere. 8(8). e142–e142. 3 indexed citations

Cao, Yue, Ye Zheng, Janaki Purushe, et al.. (2024). Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming. Blood. 144(Supplement 1). 2028–2028. 1 indexed citations

Liang, Emily C., Kai Rejeski, Teng Fei, et al.. (2024). Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity. Bone Marrow Transplantation. 59(7). 910–917. 6 indexed citations

10.

Rosen, Emily A., Elizabeth M. Krantz, Denise J. McCulloch, et al.. (2024). COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics. Transplantation and Cellular Therapy. 30(11). 1108.e1–1108.e11. 2 indexed citations

11.

Poh, Christina, Victor A. Chow, Ryan C. Lynch, et al.. (2023). Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 142(Supplement 1). 2129–2129. 1 indexed citations

12.

Fiorenza, Salvatore, Erik L. Kimble, Alexandre V. Hirayama, et al.. (2023). Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study. Transplantation and Cellular Therapy. 29(2). S13–S13. 1 indexed citations

13.

Kampouri, Eleftheria, Terry Stevens‐Ayers, Jordan Gauthier, et al.. (2023). CMV and HHV-6 after Chimeric Antigen Receptor (CAR)-T-Cell Immunotherapy for B-Cell Malignancies: A Prospective Study. Transplantation and Cellular Therapy. 29(2). S210–S211. 2 indexed citations

14.

Liang, Emily C., Alexandre V. Hirayama, Erik L. Kimble, et al.. (2023). Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.. Journal of Clinical Oncology. 41(16_suppl). 7511–7511.

15.

Kampouri, Eleftheria, Ryan Basom, Chris Davis, et al.. (2023). 2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

16.

Hirayama, Alexandre V., Cassie Chou, Takahiro Miyazaki, et al.. (2022). A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. Blood Advances. 7(11). 2479–2493. 14 indexed citations

17.

Hirayama, Alexandre V., Jordan Gauthier, Kevin A. Hay, et al.. (2019). High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 134(7). 636–640. 121 indexed citations

18.

Gauthier, Jordan, Sylvain Chantepie, Krimo Bouabdallah, et al.. (2017). Allogreffe de cellules souches hématopoïétiques dans les lymphomes diffus à grandes cellules B : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer. 104(12). S131–S135. 2 indexed citations

19.

Yakoub‐Agha, Ibrahim, Christophe Ferrand, Yves Chalandon, et al.. (2017). Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l’antigène (CAR T-cells) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer. 104(12). S43–S58. 19 indexed citations

20.

Cornillon, Jérôme, Flore Sicre de Fontbrune, Sylvain Chantepie, et al.. (2016). Dysfonctionnement du greffon et érythroblastopénie après allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer. 103(11). S248–S254. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact